Phibro Animal Health entered into an amended and restated credit agreement in which the lenders agreed to extend credit to the company in the form of term A loans in an aggregate principal amount of $300 million and a revolving credit facility in an aggregate principal amount of $250 million.
The amended and restated credit agreement:
- Has an aggregate principal amount of $550 million
- Was used to refinance the company’s June 2017 credit agreement, which consisted of an aggregate principal amount of $250 million term A loans and a $250 million revolving credit facility
- Carries substantially the same terms and conditions as the 2017 credit agreement
- Includes a $300 million term A loan, which replaces the company’s existing $250 million term A loan, reflecting a $50 million upsizing of the previous term A loan facility
- Includes a $250 million revolver, which replaces the company’s existing $250 million revolving credit facility
- Extends the maturity of the company’s credit facilities from June 2022 to April 2026
- Carries an interest rate that is consistent with the company’s current credit facilities
- Is representative of a widely syndicated group of lenders primarily consisting of the company’s existing lenders
- Was jointly arranged by BofA Securities and Coöperatieve Rabobank, with Bank of America acting as administrative agent.
_x000D_
_x000D_
_x000D_
_x000D_
_x000D_
_x000D_
_x000D_
_x000D_
_x000D_
“We are pleased to announce the refinancing of our existing credit agreement. Upsizing our existing credit facilities with primarily our existing syndicate group of lenders on substantially the same terms, conditions and pricing as our 2017 credit agreement, reflects both the company’s and lenders’ confidence in Phibro. We remain committed to continued debt and leverage reduction,” Jack Bendheim, chairman, president and CEO of Phibro, said.
